Evidence map›Paper›PMID 41070416›Full record

ArticleBJU international2026

Adverse in-hospital outcomes in patients with paraplegia who undergo radical prostatectomy.

Andrea Marmiroli, Francesco Di Bello, Natali Rodriguez Peñaranda, Mattia Longoni, Quynh Chi Le, Fabian Falkenbach, Michele Nicolazzini, Calogero Catanzaro, Zhe Tian, Jordan A Goyal and 14 more

Abstract read
In one paragraph

Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Andrea MarmiroliCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID 0009-0005-7241-8793
Francesco Di BelloCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID 0000-0002-8585-3701
Natali Rodriguez PeñarandaCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID 0009-0006-3057-3805
Mattia LongoniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Quynh Chi LeCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID 0009-0008-9209-8776
Fabian FalkenbachCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID 0000-0003-1907-3982
Michele NicolazziniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID 0009-0003-7773-5101
Calogero CatanzaroCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Zhe TianCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Jordan A GoyalCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID 0009-0006-4609-8981
Stefano LuzzagoDepartment of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.ORCID 0000-0002-9373-1413
Francesco Alessandro MistrettaDepartment of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Mattia PiccinelliDepartment of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.ORCID 0000-0003-0337-3331
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.ORCID 0000-0003-2986-5617
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Alberto BrigantiVita-Salute San Raffaele University, Milan, Italy.
Felix K H ChunDepartment of Urology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
Salvatore MicaliDepartment of Urology, Ospedale Policlinico e Nuovo Ospedale Civile S. Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy.
Nicola LongoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Markus GraefenMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Carlotta PalumboDivision of Urology, Department of Translational Medicine, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
Riccardo SchiavinaDivision of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Gennaro MusiDepartment of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo test for the association between paraplegia and perioperative complications as well as in-hospital mortality after radical prostatectomy (RP) for non-metastatic prostate cancer. PATIENTS AND

methodsWe identified patients who underwent RP (National Inpatient Sample [NIS] 2000-2019), stratified according to paraplegia status. The NIS is an inpatient database that rests on data contributed by ~20% of community hospitals within the United States. Descriptive analyses, propensity score matching (PSM, ratio 1:10), and multivariable logistic regression models (LRMs) were used.

resultsOf 260 302 patients who underwent RP, there were 223 (0.1%) with paraplegia. The patients with paraplegia who underwent RP were younger (age 60 vs 62 years; P = 0.002) and more frequently had Charlson Comorbidity Index ≥3 (46% vs 2.2%; P < 0.001). After 1:10 PSM, 223/223 (100%) patients with paraplegia and 2230/260 079 (0.9%) without paraplegia who underwent RP were included in further analyses. In multivariable LRMs, patients with paraplegia who underwent RP exhibited significantly higher in-hospital mortality (adjusted odds ratio [aOR] 10.7), higher rates of wound complications (aOR 8.2), infectious complications (aOR 6.2), genitourinary complications (aOR 3.5), intraoperative complications (aOR 2.8), cardiac complications (aOR 2.8), pulmonary complications (aOR 2.6), overall complications (aOR 2.4), blood transfusions (aOR 1.8), and longer length of stay ≥75th percentile (aOR 1.7) (all P ≤ 0.01).

conclusionAlthough patients with paraplegia who undergo RP are rare, adverse in-hospital outcomes are substantially more frequent in these individuals. These observations should be carefully considered in clinical decision making and informed consent prior to RP, if such procedure is contemplated in patients with paraplegia.

Indexed as

Hospital MortalityParaplegiaPostoperative ComplicationsProstatectomyProstatic NeoplasmsAgedHumansMaleMiddle AgedRetrospective StudiesUnited StatescomplicationsmorbidityNISparaplegiaprostate

Identifiers

PMID41070416
PMCPMC12690342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.